UK Archives -

Market Access/ News/ News/ News/ Oncology

NICE says yes to BeiGene’s Brukinsa after Scottish nay

Phil Taylor BeiGene, Brukinsa, HEOR, NICE, non-Hodgkin lymphoma, Oncology, UK 0 Comment

BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has become the first drug in the class to be recommended for routine

NICE says yes to BeiGene’s Brukinsa after Scottish nay

https://pharmaphorum.com/news/nice-says-yes-to-beigenes-brukinsa-after-scottish-nay/

Market Access/ News/ News/ News/ Oncology

NICE says no to Lynparza in prostate cancer, creates UK access divide

Phil Taylor HEOR, Lynparza, NHS, NICE, Oncology, Prostate cancer, The Institute of Cancer Research, UK 0 Comment

NICE has said it is unable to recommend NHS use of AstraZeneca’s Lynparza for some patients with prostate

NICE says no to Lynparza in prostate cancer, creates UK access divide

https://pharmaphorum.com/news/nice-says-no-to-lynparza-in-prostate-cancer-creating-uk-access-divide/

News/ News/ Patients

UK health leaders warn new PM Liz Truss of crisis-in-waiting

Phil Taylor healthcare, Liz Truss, NHS, patients, UK 0 Comment

New UK Prime Minister Liz Truss needs to take immediate action to prevent the NHS spiralling out of

UK health leaders warn new PM Liz Truss of crisis-in-waiting

https://pharmaphorum.com/news/uk-health-leaders-warn-new-pm-liz-truss-of-crisis-in-waiting/

Great Britain £50 - fifty pounds sterling notes spead out.

News

UK authority asks for director ban for Alliance Pharma CEO

Phil Taylor Alliance Pharma, antitrust, competition, NHS, pricing, regulatory, senior management, UK 0 Comment

The UK Competition and Markets Authority (CMA) is seeking to disqualify Peter Butterfield, currently chief executive of Alliance

UK authority asks for director ban for Alliance Pharma CEO

https://pharmaphorum.com/news/uk-authorities-asks-for-director-ban-for-alliance-pharma-ceo/

News/ News/ R&D

Mereo fights revolt by largest shareholder Rubric

Phil Taylor Biotech, Financial, investors, Mereo, UK 0 Comment

UK biotech Mereo BioPharma is attempting to face down a revolt by Rubric Capital Management – its largest

Mereo fights revolt by largest shareholder Rubric

https://pharmaphorum.com/news/mereo-fights-revolt-by-largest-shareholder-rubric/

Vaccine vial dose flu shot drug needle syringe,medical concept vaccination hypodermic injection treatment disease care hospital prevention immunization illness disease baby child.blue background

Market Access/ News/ News/ News/ Patients

UK advisors back Moderna’s bivalent shot for autumn COVID booster

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, JCVI, Moderna, Omicron, Spikevax, UK 0 Comment

The UK’s Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna’s bivalent COVID-19 vaccine should be

UK advisors back Moderna’s bivalent shot for autumn COVID booster

https://pharmaphorum.com/news/uk-advisors-back-modernas-bivalent-shot-for-autumn-covid-booster/

Market Access/ News/ News/ News/ Sales and Marketing

UK first to approve Moderna’s Omicron booster jab

Phil Taylor coronavirus, COVID-19, COVID-19 vaccine, MHRA, Moderna, Omicron, regulatory approval, UK 0 Comment

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed

UK first to approve Moderna’s Omicron booster jab

https://pharmaphorum.com/news/uk-first-to-approve-modernas-omicron-booster-jab/

Market Access/ News/ News/ News/ News/ Patients/ Sales and Marketing

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

Phil Taylor access, AstraZeneca, coronavirus, COVID-19, Evusheld, procurement, UK 0 Comment

Half a million people in the UK with conditions like blood cancer that prevents them being protected from

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/

Market Access/ News/ News/ News/ Oncology

Novartis’ Pluvicto gets first European approval in GB

Phil Taylor Novartis, Oncology, Pluvicto, Prostate cancer, radioligand, regulatory approval, UK 0 Comment

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light

Novartis’ Pluvicto gets first European approval in GB

https://pharmaphorum.com/news/novartis-pluvicto-gets-first-european-approval-in-gb/

Trending

UK

Login